Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Dose-escalating, Non-randomized, Single-Center Study to Determine the Safety and Pharmacokinetic Profiles of Scopolamine in Healthy Volunteers

Next Previous
Trial Profile

Open-label, Dose-escalating, Non-randomized, Single-Center Study to Determine the Safety and Pharmacokinetic Profiles of Scopolamine in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Scopolamine (Primary) ; Scopolamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Repurposed Therapeutics

Most Recent Events

  • 13 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 May 2020.
  • 13 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 May 2020.
  • 02 Dec 2019 Planned number of patients changed from 160 to 130.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top